ROCKVILLE, Md., Sept. 7 /PRNewswire/ -- Adlyfe, Inc., a privately held biotech company headquartered in Rockville, MD, focused on early diagnostics for animal and human brain diseases announced the award today of a $650,000 two year grant from the Department of Environment, Food and Rural Affairs (DEFRA) in the UK for continued development of a sensitive early blood test for animal prion diseases. Misfolded prion proteins are correlated to Sheep Scrapie disease, Mad Cow disease in cattle, Chronic Wasting Disease in Deer and Elk, and Creutzfeldt-Jakob disease in humans.
DEFRA is a leading agency in the UK with the mission of funding key emerging technologies which can thwart the spread of animal and human disease. They have a long history in supporting leading research and development in chronic diseases which impact animal and human health and impact the safety of the food supply and the environment.
The award is focused on addressing key issues in the development of the Adlyfe test that will enable early blood detection and live animal screening for disease in both sheep and cattle. Adlyfe will work in collaboration with the Moredun Institute in Scotland, a premier research institute in the field of animal disease.
"This is an important step for our company to broaden our international base of support and collaboration for development of our test for prion diseases. These diseases are global with significant impact on animal and human health. We are pleased that DEFRA recognizes the value of our technology and support continued development of our sensitive blood test for these diseases," said Alan S. Rudolph, CEO and President.
About Adlyfe, Inc: Adlyfe is a biotechnology company focused on novel blood diagnostics and therapeutics in Rockville, MD. Adlyfe develops blood diagnostic tests for early diagnosis and treatment of chronic brain 'wasting' diseases such as Mad Cow disease and Alzheimer's. They recently announced the publication of their results demonstrating detection of prion disease in early stages before clinical symptoms appear. The company is privately held and funded by NIH, DARPA and several other parties. For more information about Adlyfe, visit: http://www.adlyfe.com.
CONTACT: Alan S. Rudolph of Adlyfe, Inc., +1-301-424-8344 x203,email@example.com